Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry

Cyril William Helm, Scott D. Richard, Jianmin Pan, David Bartlett, Martin D. Goodman, Rick Hoefer, Sam S. Lentz, Edward A. Levine, Brian W. Loggie, Daniel S. Metzinger, Brigitte Miller, Lynn Parker, James E. Spellman, Paul H. Sugarbaker, Robert P. Edwards, Shesh N. Rai

Research output: Contribution to journalArticlepeer-review

81 Scopus citations


Introduction: An analysis of experience of surgical and gynecologic oncologists in the United States with the use of hyperthermic intraperitoneal chemotherapy for women with invasive epithelial ovarian cancer (EOC). Methods: An Internet-based registry (HYPER-O) collected data from collaborating institutions. Eligibility included women with EOC treated with hyperthermic intraperitoneal chemotherapy. Borderline and nonepithelial cancers were excluded. Results: As of July 1, 2008, 141 women were eligible for analysis treated at the following time points: frontline (n = 26), interval debulking (n = 19), consolidation (n = 12), and recurrence (n = 83). The mean perfusion temperatures were 38.5 to 43.6°C (median, 41.9°C) for inflow and 36.9 to 42.9°C (median, 41°C) for outflow for 30 to 120 minutes. Treatment was with a platinum agent (n = 72), mitomycin (n = 53), or a combination (n = 14). Median follow-up was 18 months (range, 0.3-140.5 months) and median overall survival 30.3 months (95% confidence interval, 23.0-37.6) with 2-, 5-, and 10-year overall survival probabilities of 49.1%, 25.4%, and 14.3%, respectively. Of the 141 patients, 110 (78%) experienced recurrence of ovarian cancer and 87 died, 3 (0.5%) dying within 30 days of surgery. In the multivariable analysis, the factors significant for increased survival were sensitivity to platinum response (P = 0.048), completeness of cytoreduction scores of 1 or 0 (P = 0.025), carboplatin alone or a combination of 2 or more chemotherapy agents used (P = 0.011), and duration of hospital stays of 10 days or less (P = 0.021). Conclusions: Hyperthermic intraperitoneal chemotherapy is a viable additional treatment option for patients with invasive EOC and may extend life in selected groups. It warrants further study in randomized controlled trials.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalInternational Journal of Gynecological Cancer
Issue number1
StatePublished - Jan 2010

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry'. Together they form a unique fingerprint.

Cite this